Skip to main content
. 2022 Feb 24;10(3):531. doi: 10.3390/biomedicines10030531

Table 1.

IC50 of diosmetin and 5-FU as monotherapy or combination therapy in HCT116 and HT29 cells.

Treatment Drug HCT116 Cells IC50 (μg/mL) HT29 Cells IC50 (μg/mL)
Monotherapy Diosmetin 4.16 ± 1.3 22.06 ± 2.7
5-FU 0.83 ± 0.0 1.65 ± 0.8
Combination therapy Diosmetin 1.38 ± 0.8 6.03 ± 0.3
5-FU 0.27 ± 1.1 1.20 ± 0.0